GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
3.005
-0.165 (-5.21%)
Nov 21, 2024, 11:53 AM EST - Market open
GT Biopharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
2
Market Cap
6.71M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ATI Physical Therapy | 728.11M |
Healthcare Triangle | 16.57M |
Plus Therapeutics | 5.73M |
Intelligent Bio Solutions | 3.19M |
Addex Therapeutics | 960.64K |
ABVC BioPharma | 509.79K |
BioCardia | 71.00K |
GTBP News
- 6 days ago - GT Biopharma Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - GlobeNewsWire
- 2 months ago - GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024 - GlobeNewsWire
- 5 months ago - GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia - GlobeNewsWire
- 6 months ago - GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 6 months ago - What made GT Biopharma stock more than double on Monday? - Invezz
- 6 months ago - GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 8 months ago - GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results - GlobeNewsWire